HCL
FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia (HCL)
September 17, 2018Sales and Marketing AstraZeneca, HCL, Lumoxiti, leukaemia, rare diseases
AstraZeneca’s Lumoxiti has been approved for use for the treatment of relapsed or refractory hairy cell leukemia (HCL)in adults who …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
